Caxton Associates LLP Castle Biosciences Inc Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Caxton Associates LLP holds 16,440 shares of CSTL stock, worth $270,931. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,440Holding current value
$270,931% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CSTL
# of Institutions
193Shares Held
26.4MCall Options Held
9.5KPut Options Held
5K-
Black Rock Inc. New York, NY3.04MShares$50.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.05MShares$33.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.47MShares$24.2 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.27MShares$20.9 Million2.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$19.8 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $433M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...